U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06792903) titled 'CG-101 Eye Drops in the Treatment of Dry Eye Syndrome' on Jan. 20.
Brief Summary: This study is a single-center, randomized, double-blind, placebo-controlled, cross-over clinical trial designed to evaluate the effectiveness and safety of CG-101 eye drops for the treatment of dry eye syndrome, using a placebo as a control.
Study Start Date: April 23, 2024
Study Type: INTERVENTIONAL
Condition:
Dry Eye
Intervention:
DRUG: CG101 high dose + artificial tear
Patient in this group received high dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group c...